Severe anaphylactic reaction after repeated intermittent exposure to lepirudin

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 760-765

  Veach, Sidney A ^a   Franks, Amy M ^a,c   Allan, Michael C ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anaphylaxis; Drug reaction; Lepirudin

Indexed keywords

LEPIRUDIN;

ADULT; ANAMNESIS; ANAPHYLAXIS; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; DECISION MAKING; DISEASE SEVERITY; HEART FAILURE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HUMAN; MALE; RISK MANAGEMENT;

ANAPHYLAXIS; ANTIBODIES; ANTICOAGULANTS; FEMALE; HEART ARREST; HIRUDINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE; MIDDLE AGED; PRACTICE GUIDELINES; RECOMBINANT PROTEINS; RESPIRATORY INSUFFICIENCY; RISK FACTORS; RISK MANAGEMENT;

EID: 34247849242     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.760     Document Type: Article

References (20)

1. Chong BH. Heparin-iuduced thrombocytopenia. J Thromb Haemost 2003;1(7):1471-8.
2. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001;103(10):1479-84.
3. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002;36(3):489-503.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344(17):1286-92.
5. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99(1):73-80.
6. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3(11):2428-36.
7. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100(6):587-93.
8. Badger NO, Butler K, Hallman LC. Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia. Pharmacotherapy 2004;24(12):1800-3.
9. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108(17):2062-5.
10. Bircher AJ, Czendlik CH, Messmer SL, Muller P, Howald H. Acute urticaria caused by subcutaneous recombinant hirudin: evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 1996;98(5 pt 1):994-6.
11. Harenberg J, Hoffmann U, Huhle G, Song X, Wang LC. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin. Br J Haematol 2000;108(3):528-30.
12. Cardenas GA, Deitcher SR. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. May Clin Proc 2005;80(4):491-3.
13. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000;96(7):2373-8.
14. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999;106(1):195-201.
15. Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100(14):1528-32.
16. Harenberg J, Huhle G, Wang LC, Hoffmann U, Song XH. Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia. Br J Haematol 2000;109:360-3.
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;31:239-45.
18. Saxer SB, Smith BS, Gandhi PJ, Tataronis GR, Krikorian SA. Recommended and actual lepirudin doses in patients with renal insufficiency. Am J Health-Syst Pharm 2003;60(24):2588-93.
19. Berlex Laboratories. Refludan (lepirudin) package insert. Montville, NJ; 2004.
20. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004;103(2):613-16.